Medicine and Dentistry
Low Drug Dose
100%
Cell Function
100%
Beta Cell
100%
Gliclazide
100%
Incretin
100%
Type 2 Diabetes
27%
Oral Glucose Tolerance Test
27%
Blood Glucose
18%
Hypoglycemia
18%
Sulfonylurea
18%
Insulin Release
18%
Diabetes
9%
Glycon
9%
Patient with Type 2 Diabetes
9%
Infusion
9%
Monotherapy
9%
Hemoglobin A1c
9%
Scanning Electron Microscopy
9%
Single Drug Dose
9%
Keyphrases
β-cell Function
100%
Gliclazide
100%
Incretin Effect
100%
Type 2 Diabetes Mellitus (T2DM)
27%
Sulfonylurea
18%
Insulin Secretion
18%
Plasma Glucose
18%
Oral Glucose Tolerance Test
18%
Low Blood Glucose
18%
Incretin Action
18%
Plasma Concentration
9%
B Cells
9%
Hypoglycemia Risk
9%
Hypoglycemia
9%
Type 2 Diabetic Patients
9%
Oral Glucose
9%
Incretin
9%
Permanent Neonatal Diabetes
9%
Metformin Monotherapy
9%
Hemoglobin A1c (HbA1c)
9%
Glucose Sensitivity
9%
Potentiation
9%
Beta Cell Glucose Sensitivity
9%
Glucose Concentration
9%
Cell Modeling
9%
Upper Quartile
9%
Function Modeling
9%
Biochemistry, Genetics and Molecular Biology
Cell Function
100%
Gliclazide
100%
Low Drug Dose
100%
Incretin
100%
Glucose Blood Level
27%
Sulfonylurea
18%
Insulin Release
18%
Glucose Test
18%
Glucose Tolerance Test
18%
Blood Level
9%
Glycosylated Hemoglobin
9%
Scanning Electron Microscopy
9%
Single Drug Dose
9%
Pharmacology, Toxicology and Pharmaceutical Science
Gliclazide
100%
Incretin
100%
Sulfonylurea
18%
Hypoglycemia
18%
Metformin
9%
Monotherapy
9%
Scanning Electron Microscopy
9%
Hemoglobin A1c
9%
Non Insulin Dependent Diabetes Mellitus
9%